Re:Cognition Health Wins SME500 UK 2026 Award: Pioneering Brain and Mind Health Innovation

Re:Cognition Health has been honoured with the SME500 UK 2026 Award, a prestigious accolade recognising the most outstanding small and medium-sized enterprises across the UK. This award celebrates Re:Cognition Health’s exceptional contributions to brain and mind health, highlighting its pioneering clinical services, global research leadership, and unwavering commitment to patient-centred care.

Founded as a specialist brain and mind clinic, Re:CognitionHealth is dedicated to the diagnosis, treatment, and care of individuals experiencing cognitive impairment. Its clinical expertise spans traumatic brain injury, neurology, children’s neurological conditions, Alzheimer’s and dementia, mental health, long Covid, and chronic traumatic encephalopathy (CTE). With clinics in both the UK and USA, Re:Cognition Health is also a major centre for international clinical trials of disease-modifying and symptomatic drugs for Alzheimer’s disease and other neurological conditions.

At the heart of Re:Cognition Health’s mission is a vision to transform brain and mind health through early diagnosis, innovative treatment, and global education. The organisation is driven by core values of innovation, compassion, collaboration, and patient-centred care. Its multidisciplinary team of experts delivers integrated services for a wide spectrum of neurological, neuropsychiatric, and neurodiverse conditions, including autism, ADHD, PTSD, and long Covid.

Re:Cognition Health stands out for its unique clinical model, which prioritises early diagnosis and seamless access to global clinical trials. Patients benefit from early access to groundbreaking therapies such as Leqembi and Kisunla, now available privately through Re:Cognition Health’s clinics in the UK and USA. The organisation’s purpose-built clinics are designed to promote calm and comfort, with sensory-conscious environments and dedicated neurodiversity-friendly zones for children.

In 2024, Re:Cognition Health opened its new 8,000 sq. ft flagship clinic on Harley Street in London, uniting all London services under one roof. This centre offers private care, clinical trials, and medico-legal assessments in a tranquil setting, attracting patients from across Europe and beyond for novel Alzheimer’s treatments not yet available in Europe.

Re:Cognition Health is also a leader in public education and advocacy. In 2024, the organisation contributed to the BBC’s Panorama: Alzheimer’s – A Turning Point, raising national awareness of the importance of early diagnosis and access to clinical trials. Founder Dr Emer MacSweeney’s TEDx talk on CTE has reached over four million viewers globally, sparking international dialogue across healthcare, sport, and education.

The organisation’s impact extends beyond clinical care. In 2024, Re:Cognition Health launched the Brain and Mind Foundation, a charitable initiative supporting global research, public education, and help for those affected by underserved neurological conditions. Sustainability is also a key focus, with eco-conscious clinic design and carbon neutrality efforts in partnership with Minimum.com since 2020.

Re:Cognition Health’s physicians have contributed to numerous peer-reviewed medical publications and over 500 media articles, offering trusted clinical perspectives on a broad range of neurological and mental health topics. This sustained engagement has informed the public and influenced professional practice and policy discussions within the sector.

The SME500 UK 2026 Award recognises Re:Cognition Health’s exceptional clinical impact, innovation in diagnostics, and commitment to advancing brain and mind health. The organisation’s achievements set a global benchmark for excellence in independent brain and mind health services, transforming lives today and shaping the future of cognitive healthcare for generations to come.

For more information about Re:Cognition Health and its services, visit www.recognitionhealth.com.

‍